The potential use of radionuclides in therapy has been recognized for many decades. A
number of radionuclides, such as iodine-131 (131 I), phosphorous-32 (32 P), strontium-90 …

The landscape of prostate cancer treatment is rapidly changing as extensive research into
potential therapies yields new options. In this article, the literature is reviewed to identify …

Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and
results in serious symptoms and complications such as bone pain, pathological fractures …

Skeletal metastases occur in many patients with different kinds of malignant tumors,
especially in advance stage of breast cancer (in 47%–85% of patients), prostate cancer (33 …

Metastatic tumours of the bone are the most common types of bone cancer. Autopsy studies
have shown that 70% of patients with breast and prostate carcinoma develop skeletal …

Bone pain arising from secondary skeletal malignancy constitutes one of the most common
types of chronic pain among patients with cancer which can lead to rapid deterioration of the …

Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence
of castrate levels of androgens and remains sensitive to further hormonal manipulation. For …

Background and Aims Approximately 85% of patients with cancer suffer severe metastatic
bone pain for which radionuclide therapy has been employed for pain palliation. We …

Background Bone metastases occur frequently in patients with solid tumours such as those
of the prostate, breast and lung, and are associated with an increased risk of skeletal-related …

Application of bone-seeking radiopharmaceuticals is one of the modalities in the
management of metastatic bone pain. The present study aimed to investigate the potential of …